2026年4月24日，Sonoma Pharmaceuticals, Inc.与Dawson James证券公司正式签署承销协议。该协议已通过美国证券交易委员会（SEC）备案程序，标志着双方资本合作进入实质性阶段。
根据公开披露的SEC文件显示，此次承销协议的签署将为企业后续资本运作奠定基础。作为专业医疗健康领域的上市公司，Sonoma Pharmaceuticals此举引发市场对其未来战略布局的广泛关注。
2026年4月24日，Sonoma Pharmaceuticals, Inc.与Dawson James证券公司正式签署承销协议。该协议已通过美国证券交易委员会（SEC）备案程序，标志着双方资本合作进入实质性阶段。
根据公开披露的SEC文件显示，此次承销协议的签署将为企业后续资本运作奠定基础。作为专业医疗健康领域的上市公司，Sonoma Pharmaceuticals此举引发市场对其未来战略布局的广泛关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.